Incannex Healthcare Limited – Edison Research Report

Edison Group, a respected global investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac, yesterday published a research report on Incannex Healthcare Limited (ASX: IHL, NASDAQ: IXHL). The report places a risk adjusted NPV valuation of US$11.42 per ADR compared to the last traded price of US$4.35 per ADR.

Interestingly, the valuation is made up of 92% for IHL-42X (Incannex’s sleep Apnoea drug), 1% for psylocibin / psychotherapy (currently in a phase 2A trial for generalised anxiety disorder) and 7% for cash. No value has been placed on any other assets currently owned and under development by Incannex. This reinforces our belief that there is significant upside in Incannex shares from the current level of A$0.235 per share.

Please follow the link below to access the report.